Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? by unknown
Bauml et al. Breast Cancer Research  (2015) 17:89 
DOI 10.1186/s13058-015-0599-7RESEARCH ARTICLE Open AccessArthralgia among women taking aromatase
inhibitors: is there a shared inflammatory
mechanism with co-morbid fatigue and insomnia?
Joshua Bauml1,2, Lu Chen3, Jinbo Chen3, Jean Boyer4, Michael Kalos5, Susan Q. Li3,6, Angela DeMichele1,2,3
and Jun J. Mao1,3,6*Abstract
Introduction: Arthralgia is a common toxicity among women taking aromatase inhibitors (AIs) and can lead to
premature discontinuation of therapy. We evaluated the association between arthralgia, co-morbid fatigue and/or
insomnia, and inflammatory biomarkers among women taking AIs.
Methods: Women taking AIs for early-stage breast cancer completed a modified version of the Brief Pain Inventory,
the Brief Fatigue Inventory, and the Insomnia Severity Index and provided blood samples for simultaneous
assessment of 34 inflammatory biomarkers with a Luminex kit. Two-sided t tests were used to compare
inflammatory biomarker concentrations for patients with or without moderate to severe arthralgia. Multivariate
linear regression analyses were performed to evaluate the relationship between comorbid arthralgia, fatigue, and
insomnia with identified biomarker concentrations.
Results: Among 203 participants, the severity of arthralgia, fatigue, and insomnia were significantly correlated
with each other (p < 0.001 for all comparisons). After controlling for race, chemotherapy history, non-steroidal
anti-inflammatory drug use, age, and body mass index, the coexistence of arthralgia, fatigue, and insomnia was
associated with elevated C-reactive protein (CRP) (β = 93.1; 95 % confidence interval (CI): 25.1–161.1; p = 0.008),
eotaxin (β = 79.9; 95 % CI: 32.5–127.2; p = 0.001), monocyte chemoattractant protein (MCP)-1 (β = 151.2; 95 % CI:
32.7–269.8; p = 0.013), and vitamin D–binding protein (VDBP) (β = 19,422; 95 % CI: 5500.5–33,344; p = 0.006).
Conclusions: Among women taking AIs, the coexistence of arthralgia, fatigue, and insomnia was associated with
increased levels of inflammatory biomarkers (elevated CRP, eotaxin, MCP-1, and VDBP). These findings suggest a
possible shared inflammatory mechanism underlying these common symptoms.Introduction
Aromatase inhibitors (AIs) are an important component
of the standard treatment of hormone receptor–positive
breast cancer, but a high incidence of arthralgia (joint
pain) may lead to premature therapy discontinuation
and increased mortality [1, 2]. Although up to 47 % of
women taking AIs report arthralgia [3], current under-
standing of the mechanisms underlying AI-associated
arthralgia is limited.* Correspondence: jun.mao@uphs.upenn.edu
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are associated with an increase is systemic inflammation,
which can exacerbate joint pain syndromes [4–8]. Given
the precipitous drop in estrogen levels associated with
AI administration [9], AI-associated arthralgia could be
a result of similar immunomodulation. Imaging studies
have revealed inflammatory tenosynovial changes at sites
of AI-associated arthralgia, and a genome-wide associ-
ation study revealed four single-nucleotide polymorphisms
(SNPs) linking AI-associated arthralgia and T-cell ma-
turation [10, 11]. Prior efforts to evaluate the association
between AI-associated arthralgia and systemic inflam-
mation have been limited by small sample sizes [12, 13].
In contrast, fatigue and insomnia, which are often coexist-
ent with pain in patients with cancer [14], have beenticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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the coexistence of arthralgia, fatigue, and insomnia is one
of the more common symptom clusters experienced by
breast cancer survivors [18, 19].
We aimed to evaluate the association of moderate to
severe arthralgia with plasma inflammatory biomarker
concentrations among postmenopausal women with
early-stage breast cancer who were currently taking AIs.
We hypothesized that the presence of moderate to se-
vere arthralgia would be associated with elevated serum
inflammatory biomarker concentrations. Because arth-
ralgia often coexists with fatigue and insomnia [19], we
then evaluated the association of the simultaneous ex-
perience of arthralgia, fatigue, and insomnia with inflam-
matory biomarkers. We hypothesized that the molecules
identified in aim 1 would also be positively correlated
with the coexistence of arthralgia, fatigue, and insomnia.
Methods
Study design and patients
We conducted a cross-sectional study, drawing our sam-
ple from an ongoing cohort study of patients receiving
adjuvant AI therapy in the outpatient breast oncology
clinic in the Abramson Cancer Center at the University
of Pennsylvania between 2008 and 2013. Eligible partici-
pants were aged 18 years or older, had a diagnosis of
early-stage breast cancer (stages I–III), were taking an
AI, and had a Karnofsky score ≥60 (i.e., ambulatory).
Additional inclusion criteria required the completion of
all chemotherapy and radiation therapy at least 1 month
before enrollment, approval of the patient’s treating
oncologist, and the ability of the patient to understand
and provide informed consent in English. After provid-
ing informed consent, patients completed a series of
patient-reported outcome instruments and provided a
non-fasting blood sample for analysis. Self-report ques-
tionnaires and chart abstraction were used for demo-
graphic and clinical information. For the present study,
we included 203 participants who had had both survey
data and a blood sample available during the time of
biomarker analyses. The Institutional Review Board at
the University of Pennsylvania approved this study.
Symptom measurement
Arthralgia was measured using a modified version of the
Brief Pain Inventory (BPI). Because we were focused on
arthralgia, the questions were modified to evaluate pain
in and around joints. The BPI is validated in patients
with cancer and is one of the most commonly used in-
struments used to measure pain. Domains measured are
pain severity (four items) and interference (seven items),
with Cronbach’s α ranging from 0.8 to 0.87 and from
0.89 to 0.92, respectively [20]. The use of a single item
on the instrument, “Worst pain in the last 24 hours,”has previously been validated for use of the BPI as a
dichotomous measure to define moderate to severe
pain [21]. Our group has previously shown that a cut
point ≥4 on this item was associated with greater
likelihood to discontinue AI therapy prematurely [1].
Fatigue was measured using the Brief Fatigue Inventory
(BFI). The BFI has been validated in cancer populations
(Cronbach’s α = 0.96). Similar to the BPI, the “worst fa-
tigue” item has been validated as a single-item dichotom-
ous variable, with a cut point ≥4 indicating moderate to
severe fatigue [22]. Insomnia was measured using the
Insomnia Severity Index, a seven-item survey validated in
the assessment of insomnia severity among patients with
cancer with a Cronbach’s α ranging from 0.76 to 0.78. A
cut point >14 on the overall score has been validated as a
dichotomous measure for the presence or absence of
moderate to severe insomnia [23].
Inflammatory biomarker measurement
Serum levels of cytokines, chemokines, and inflam-
matory molecules were determined using the Cytokine
Human Magnetic 30-Plex Panel for the Luminex plat-
form (Life Technologies, Carlsbad, CA, USA) and the
Acute Phase Human 4-Plex Panel for the Luminex plat-
form (Life Technologies). With the 30-plex assay, we ex-
amined the following serum cytokine and chemokine
levels: interleukin (IL)-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-15, IL-17,
vascular endothelial growth factor, tumor necrosis factor
α, interferon (IFN)-α, IFN-γ, granulocyte macrophage
colony-stimulating factor, macrophage inflammatory
protein (MIP)-1α, MIP1-β, IFN-γ-inducible protein 10,
monokine induced by interferon gamma, eotaxin, the reg-
ulated on activation, normal T expressed and secreted
protein (RANTES), monocyte chemoattractant protein
(MCP)-1, epidermal growth factor, granulocyte colony-
stimulating factor, basic fibroblast growth factor, and hep-
atocyte growth factor. Sera were defrosted on ice and
added undiluted to the beads. Incubation and washing
were carried out per assay specifications. With the 4-plex
acute phase panel, we examined β2-microglobulin, C-
reactive protein (CRP), haptoglobin, and vitamin D–bind-
ing protein (VDBP or Gc globulin). Sera were diluted as
suggested to a 1:8000 concentration. The diluted sample
was added to the magnetic beads, followed by incubation
and washing per assay specifications.
Statistical analysis
Descriptive statistics were used to evaluate the distribu-
tion of scores on each of the three patient-reported out-
come instruments, with which we measured arthralgia,
fatigue, and insomnia. Patients were then dichotomized
into the presence or absence of moderate to severe arth-
ralgia, fatigue, and insomnia, as defined by the cut points
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pairwise correlations among the three symptoms.
We explored the variability in each inflammatory bio-
marker using box plots. We identified 20 biomarkers
with limited intersubject variability. These were excluded
from further analyses. We assessed pairwise correlations
among the 14 remaining biomarkers, which revealed a
significant association. To understand whether the vari-
ability in inflammatory biomarkers could be explained
by clinical and demographic variables, we performed a
series of linear regressions to evaluate the association of
our collected clinical and demographic variables with in-
flammatory biomarker concentration. With our identi-
fied inflammatory biomarkers, we specifically assessed
the association of each cytokine marker with age, race,
non-steroidal anti-inflammatory drug (NSAID) use in
the last 7 days, body mass index (BMI), education, years
since last menstrual period, history of chemotherapy ad-
ministration (with a specific focus on taxane history,
given the risk for acute taxane induced neuropathy,
which can present as joint pain), cancer stage, and years
on AIs. Any variable with a p value ≤0.1 was included in
our final model.
For the primary hypothesis, we conducted two-sided t
tests to compare the mean concentration of each inflam-
matory biomarker for patients with and without moder-
ate to severe arthralgia. The Bonferroni adjustment was
applied to adjust for multiplicity in testing (p < 0.004).
For the secondary hypothesis, we created a composite
binary variable to identify patients with all three symptoms
versus those with fewer symptoms. We then conducted
two-sided t tests to compare the mean concentration of
each inflammatory biomarker for patients with and with-
out comorbid symptoms. Finally, we performed multivari-
ate linear regression analysis to reevaluate the associations
between symptoms and inflammatory biomarkers after
adjusting for confounding variables.
Results
Patient characteristics
The demographic and clinical characteristics of study
participants are shown in Table 1. Our analysis included
203 patients. Their mean age was 60.5 years, and 80.7 %
of them were white. The stage distribution was as fol-
lows: 47 % in stage 0/I, 40.5 % in stage II, and 12.5 % in
stage III. The most common AI used was anastrozole,
which was used by 74.4 % of participants. Chemotherapy
had been administered to 61.7 % of patients surveyed.
Prevalence and correlation of key symptoms
Using the cut points of moderate to severe symptoms
defined above, 21.3 % of patients had arthralgia, 41.6 % of
patients had fatigue, and 33.2 % had insomnia. Arthralgia
was significantly correlated with fatigue (r = 0.56, p < 0.001),and 88.4 % of patients with arthralgia also had fatigue.
Arthralgia was also significantly correlated with insomnia
(r = 0.49, p < 0.001), and 83.7 % of patients with arthralgia
also had insomnia. Of the overall population, 16.8 % of
patients had all three symptoms. The demographic and
clinical characteristics of study participants, as a function
of the presence or absence of all three symptoms, are
shown in Table 1.
Association between arthralgia, fatigue, and insomnia
with biomarkers
The biomarkers exhibited significant pairwise correlation
(Additional file 1: Table S1). As such, a multivariable
model including all inflammatory biomarkers was not
constructed. As can be seen in Figs. 1, 2, 3, and 4, higher
concentrations of CRP (p = 0.0026), eotaxin (p = 0.0002),
MCP-1 (p = 0.0017), and VDBP (p = 0.0006) were associ-
ated with moderate to severe arthralgia. These results
were all statistically significant after correction for mul-
tiple comparisons. In an exploratory analysis of fatigue
and insomnia, all of these biomarkers also showed an
association with fatigue and insomnia, with the exception
of a trend toward significance for CRP and insomnia.
Additional file 2: Tables S2–S4 describe the results of all
two-sided t tests done to evaluate the association of each
symptom with inflammatory biomarkers.
Association of composite symptom variable with
inflammatory biomarkers
We performed a series of linear regressions to evaluate
the association of our composite symptom burden vari-
able with biomarker concentrations, controlling for BMI,
race, chemotherapy status, NSAID use, and age. BMI,
NSAID use, and race were associated with inflammatory
biomarker concentrations in our sample (data not
shown), whereas chemotherapy and age have been
shown in other series to impact arthralgia and inflamma-
tory biomarker concentrations [15, 24, 25]. CRP (β =
93.1; 95 % confidence interval [CI]: 25.1–161.1; p =
0.008), eotaxin (β = 79.9; 95 % CI: 32.5–127.2; p = 0.001),
MCP-1 (β = 151.2; 95 % CI: 32.7–269.8; p = 0.013), and
VDBP (β = 19,422; 95 % CI: 5500.5–33,344; p = 0.006)
were strongly associated with the presence of all three
symptoms in multivariate analyses (see Table 2).
Discussion
Arthralgia is a common side effect among women taking
AIs and is associated with premature discontinuation of
therapy [1]. Non-adherence to a 5-year regimen of AIs is
associated with increased mortality [2]. Unfortunately,
current understanding of this toxicity is limited. We
found that moderate to severe arthralgia is associated
with specific serum markers of inflammation (elevated
CRP, eotaxin, MCP-1, and VDBP) among women taking
Table 1 Participant characteristics (N = 203)
Overall population With symptom cluster Without symptom cluster
Mean age (SD) 60.5 (8.5) yr 60.1 (9.4) yr 60.6 (8.3) yr
Body mass index (kg/m2)
Normal weight (18.5–24.9) 83 (41.1 %) 9 (26.5 %) 74 (44 %)
Overweight (25–29.9) 59 (29.2 %) 12 (35.3 %) 47 (28 %)
Obese (>30) 60 (29.7 %) 13 (38.2 %) 47 (28 %)
Race
White 163 (80.7 %) 26 (76.5 %) 137 (81.5 %)
Non-white 39 (19.3 %) 8 (23.5 %) 31 (18.5 %)
Education
High school or less 46 (22.8 %) 8 (23.5 %) 38 (22.6 %)
College 93 (46 %) 20 (58.8 %) 73 (43.5 %)
Graduate/professional 63 (31.2 %) 6 (17.7 %) 57 (33.9 %)
Years since LMP
<5 yr 41 (21.5 %) 13 (40.6 %) 80 (50.3 %)
5–10 yr 57 (29.8 %) 10 (31.3 %) 47 (29.6 %)
>10 yr 93 (48.7 %) 9 (28.1 %) 32 (20.1 %)
Cancer stage
Stage 0/I 94 (47 %) 13 (38.2 %) 81 (48.8 %)
Stage II 81 (40.5 %) 16 (47.1 %) 65 (39.2 %)
Stage III 25 (12.5 %) 5 (14.7 %) 20 (12 %)
AI taken
Anastrozole 148 (74.4 %) 27 (79.4 %) 121 (73.3 %)
Exemestane 20 (10 %) 2 (5.9 %) 18 (10.9 %)
Letrozole 31 (15.6 %) 5 (14.7 %) 26 (15.8 %)
Years on AI
<1 yr 54 (26.7 %) 11 (32.4 %) 43 (25.6 %)
1–3 yr 85 (42.1 %) 12 (35.3 %) 73 (43.5 %)
>3 yr 63 (31.2 %) 11 (32.3 %) 52 (30.9 %)
Chemotherapy history
None 77 (38.3 %) 14 (41.2 %) 63 (37.7 %)
Regimen with a taxane 78 (38.8 %) 10 (29.4 %) 36 (21.6 %)
Regimen without a taxane 46 (22.9 %) 10 (29.4 %) 68 (40.7 %)
NSAID use in last 7 days
Yes 61 (30.3 %) 17 (50 %) 44 (26.3 %)
No 138 (68.7 %) 17 (50 %) 121 (72.5 %)
Don’t know 2 (1 %) 0 (0 %) 2 (1.2 %)
AI aromatase inhibitor, LMP last menstrual period, NSAID non-steroidal anti-inflammatory drug, SD standard deviation
Symptom cluster refers to comorbid arthralgia, fatigue, and insomnia
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arthralgia, fatigue, and insomnia was associated with ele-
vated serum biomarker concentrations. These data sug-
gest that inflammation may be a shared mechanism of
these toxicities.
Our findings are consistent with prior research tying
estrogen deprivation to inflammation. Estrogen α- andβ-receptors in the nucleus alter gene expression of
various inflammatory biomarkers, leading to immuno-
modulation [5]. Indeed, estrogen supplementation seems
to ameliorate certain autoimmune conditions [4], and
women going through menopause can experience an
exacerbation of inflammatory conditions, such as fibro-
myalgia and rheumatoid arthritis [7, 8].
Fig. 2 Association of individual symptoms with eotaxinFig. 1 Association of individual symptoms with C-reactive protein (CRP)
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have evaluated the contribution of inflammation to
AI-associated arthralgia. In a genome-wide association
study, Ingle et al. identified a series of SNPs that
were correlated with the presence of AI-associated
arthralgia [11]. These SNPs centered on T-cell leukemia/
lymphoma protein 1A (TCL1A), an inflammatory protein
whose activity is modulated by estrogen levels. The SNP
variations associated with AI-associated arthralgia resulted
in TCL1A levels that were more sensitive to estrogen
variation. Researchers in two prior studies have explored
the association of serum inflammatory biomarkers withAI-associated arthralgia [12, 13]. Although neither of these
studies revealed an association between arthralgia and
systemic inflammation, both were limited by small
sample sizes.
Our research found that arthralgia is significantly asso-
ciated with fatigue and insomnia. Among those experi-
encing moderate to severe arthralgia, 88.4 % also had
fatigue and 83.7 % also had insomnia. Bower et al. have
evaluated the association of inflammatory biomarkers
with fatigue both during [26] and after primary treatment
[15] for breast cancer. Consistent with our findings, they
noted that CRP elevations were associated with fatigue
Fig. 4 Association of individual symptoms with vitamin D–binding
protein (VDBP)
Fig. 3 Association of individual symptoms with monocyte
chemoattractant protein (MCP)-1
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of IL-6, which is the principal stimulatory molecule for
the secretion of CRP [5, 6]. It thus may not be surprising
that patients have elevated CRP levels during treatment
for breast cancer, when estrogen levels fall significantly.
Our data suggest that these symptoms often coexist and
that inflammation may underlie the mechanism of these
common symptoms; therefore, interventions targeting in-
flammation may play a role in addressing these symptoms
simultaneously.Our identification of VDBP, eotaxin, and MCP-1 as
relevant inflammatory biomarkers for AI-related symp-
tom burden is novel. VDBP is the primary binding pro-
tein for vitamin D, but it is also an acute-phase reactant
subject to significant genetic variability [27–31]. VDBP
is thus a particularly intriguing mechanistic molecule,
given accumulating evidence that vitamin D may have
an important role in a wide variety of disease states [32].
Indeed, high-dose vitamin D supplementation was associ-
ated with a decreased incidence of AI-associated arthralgia
in one study [33]. Eotaxin and MCP-1 are chemokines
Table 2 Association of symptom cluster (arthralgia, fatigue, and insomnia) with inflammatory biomarkers
Univariate analysis Multivariate analysis
Coefficient (95 % CI) p value Coefficient (95 % CI) p value
CRP 117.3 (49.3–185.3) 0.001 93.1 (25.1–161.1) 0.008
Eotaxin 87.3 (40.8–133.7) <0.001 79.9 (32.5–127.2) 0.001
MCP-1 178 (63–293.2) 0.003 151.2 (32.7–269.8) 0.013
VDBP 21,530.8 (8088.4–34,973.2) 0.002 19,422 (5500.5–33,344) 0.006
Data shown are results of multivariate linear regression analyses controlled for race, body mass index, chemotherapy status, non-steroidal anti-inflammatory drug
use, and age
CI confidence interval, CRP C-reactive protein, MCP-1 monocyte chemoattractant protein 1, VDBP vitamin D–binding protein
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sites of injury [34, 35]. Elevated eotaxin and MCP-1 con-
centrations have been seen in patients with fibromyalgia
[36], another condition characterized by joint pain, insom-
nia, and fatigue [37].
Our study has a number of important limitations.
First, it was cross-sectional in nature. As such, we are
unable to establish the causal relationship between
symptom burden and inflammatory biomarkers. Further
prospective work is needed to clarify whether systemic
inflammation leads to symptoms or if the persistent
symptoms cause inflammation. Second, we examined
numerous biomarkers in this study, and there is a risk of
false-positive discovery. We adjusted our primary ana-
lysis using Bonferroni corrections for those biomarkers
that demonstrated variability in our sample. A future
replication study is needed to verify the results identified
in our study. Third, our biomarker sampling was non-
fasting, and we did not have complete data on comorbid
conditions or other medications patients may have used,
including statins and bisphosphonates. As described
above, concurrent autoimmune conditions may also affect
biomarker concentrations [36]. Future studies should con-
trol for these variables.
In spite of these limitations, this study is, to the best
of our knowledge, the largest study to date evaluating
the association of patient-reported symptoms with in-
flammatory biomarkers. We demonstrated that patient-
reported arthralgia and co-morbid fatigue and insomnia
are associated with elevated serum inflammatory bio-
markers among women taking AIs. A better understand-
ing of this novel finding will allow clinicians to develop
strategies to manage these symptoms to improve quality
of life, adherence to AI therapies, and potentially sur-
vival outcomes for women with breast cancer.
Conclusions
Patient-reported arthralgia and co-morbid fatigue and
insomnia were associated with elevated CRP, eotaxin,
MCP-1, and VDBP among a group of breast cancer sur-
vivors taking AIs. A better understanding of symptom-
atic causes of distress will allow clinicians to develop
strategies to manage these symptoms to improve qualityof life, adherence to therapy, and potentially survival
outcomes for women with breast cancer.Additional files
Additional file 1: Table S1. Pairwise correlation between inflammatory
biomarkers.
Additional file 2: Tables S2–S4. Two-sided t tests of inflammatory
biomarker concentrations as a function of symptoms.
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